I would counsel Anne on the risks of taking her medication early or inconsistently with the dosing instructions. I would explain that early refills can lead to misuse and potential addiction issues. I would explore reasons she may be taking the medication early and address any concerns. I would monitor the situation closely and consider a pain management contract if needed to ensure her safety and appropriate use of the medication.
This document provides an overview of a training module on proper prescribing of controlled prescription drugs. It discusses the objectives of the training, which are to discuss the controlled prescription drug epidemic, define misprescribing, compare the roles of the medical board and DEA, and determine one's risk for misprescribing. It also provides information on the rights and responsibilities around the materials, introduces the topics that will be covered, and gives instructions for how to complete the module.
The document summarizes the 2015 update of the American Geriatrics Society Beers Criteria, which provides a list of potentially inappropriate medications that should generally be avoided in older adults. Key points:
- The updated criteria include revisions to existing medications to avoid as well as new sections on medications requiring dose adjustments for kidney function and drug-drug interactions.
- A 13-member expert panel reviewed evidence and reached consensus on the criteria using a systematic, evidence-based process.
- The criteria are intended to improve medication safety for older adults by providing guidance to medical professionals, consumers, and health systems.
Duplication prescribing and misuse of medicine can harm patients and lead to death. Duplication prescribing occurs when multiple medications are prescribed for the same condition without coordination. Misuse involves using medication other than as intended, such as through addiction. Strategies to reduce these risks include implementing electronic health records and clinical decision support to avoid therapeutic duplication, educating patients, and enhancing prescription drug monitoring programs and enforcement of drug disposal laws.
- The study examined how Medicare Part D enrollment affected out-of-pocket prescription costs and medication use among Medicare beneficiaries with cardiovascular disease. Nearly 49% of these beneficiaries enrolled in Part D plans.
- Those without prior drug coverage reported their monthly out-of-pocket costs decreased the most and were more likely to increase their use of cardiovascular medications after enrolling in Part D.
- Dual-eligible beneficiaries (covered by both Medicare and Medicaid) reported their out-of-pocket costs increased the most and were less likely to use cardiovascular medications after shifting to Part D plans.
Mystified by MAT? Navigating the Changing Regulatory Landscape Around Medicat...Epstein Becker Green
Part of a "first Thursdays" fall webinar series hosted by Behavioral Health Association of Providers, Epstein Becker & Green, P.C., and Nelson Hardiman, LLP.
Presented by:
Francesca R. Ozinal – Associate, Epstein Becker Green
Andrew Martin – Chief Operating Officer, Behavioral Health Association of Providers
Despite reports identifying medication-assisted treatment (MAT) as a critical element of evidence-based treatment, confusion concerning who may dispense, associated compliance requirements, and the relationship between MAT provision and behavioral health providers continues to impede access to MAT.
This webinar will review key licensing and operational issues concerning the various types of MAT, including buprenorphine, naltrexone, and methadone, as well as misperceptions and key compliance issues in instituting MAT.
More info: https://www.ebglaw.com/events/mystified-by-mat-navigating-the-changing-regulatory-landscape-around-medication-assisted-treatment/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
I would counsel Anne on the risks of taking her medication early or inconsistently with the dosing instructions. I would explain that early refills can lead to misuse and potential addiction issues. I would explore reasons she may be taking the medication early and address any concerns. I would monitor the situation closely and consider a pain management contract if needed to ensure her safety and appropriate use of the medication.
This document provides an overview of a training module on proper prescribing of controlled prescription drugs. It discusses the objectives of the training, which are to discuss the controlled prescription drug epidemic, define misprescribing, compare the roles of the medical board and DEA, and determine one's risk for misprescribing. It also provides information on the rights and responsibilities around the materials, introduces the topics that will be covered, and gives instructions for how to complete the module.
The document summarizes the 2015 update of the American Geriatrics Society Beers Criteria, which provides a list of potentially inappropriate medications that should generally be avoided in older adults. Key points:
- The updated criteria include revisions to existing medications to avoid as well as new sections on medications requiring dose adjustments for kidney function and drug-drug interactions.
- A 13-member expert panel reviewed evidence and reached consensus on the criteria using a systematic, evidence-based process.
- The criteria are intended to improve medication safety for older adults by providing guidance to medical professionals, consumers, and health systems.
Duplication prescribing and misuse of medicine can harm patients and lead to death. Duplication prescribing occurs when multiple medications are prescribed for the same condition without coordination. Misuse involves using medication other than as intended, such as through addiction. Strategies to reduce these risks include implementing electronic health records and clinical decision support to avoid therapeutic duplication, educating patients, and enhancing prescription drug monitoring programs and enforcement of drug disposal laws.
- The study examined how Medicare Part D enrollment affected out-of-pocket prescription costs and medication use among Medicare beneficiaries with cardiovascular disease. Nearly 49% of these beneficiaries enrolled in Part D plans.
- Those without prior drug coverage reported their monthly out-of-pocket costs decreased the most and were more likely to increase their use of cardiovascular medications after enrolling in Part D.
- Dual-eligible beneficiaries (covered by both Medicare and Medicaid) reported their out-of-pocket costs increased the most and were less likely to use cardiovascular medications after shifting to Part D plans.
Mystified by MAT? Navigating the Changing Regulatory Landscape Around Medicat...Epstein Becker Green
Part of a "first Thursdays" fall webinar series hosted by Behavioral Health Association of Providers, Epstein Becker & Green, P.C., and Nelson Hardiman, LLP.
Presented by:
Francesca R. Ozinal – Associate, Epstein Becker Green
Andrew Martin – Chief Operating Officer, Behavioral Health Association of Providers
Despite reports identifying medication-assisted treatment (MAT) as a critical element of evidence-based treatment, confusion concerning who may dispense, associated compliance requirements, and the relationship between MAT provision and behavioral health providers continues to impede access to MAT.
This webinar will review key licensing and operational issues concerning the various types of MAT, including buprenorphine, naltrexone, and methadone, as well as misperceptions and key compliance issues in instituting MAT.
More info: https://www.ebglaw.com/events/mystified-by-mat-navigating-the-changing-regulatory-landscape-around-medication-assisted-treatment/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
This study examined opioid prescribing patterns among Medicaid patients and providers in Oregon in 2013. It found that prescribing and use were highly concentrated, with the top 10% of providers accounting for over 80% of opioid prescriptions by morphine equivalent dose, and the top 10% of patients accounting for over 83% of doses. Patients in the highest decile of opioid use had higher rates of potential misuse indicators like prescription overlaps. While increasing opioid use overall was linked to higher misuse, receiving opioids from the highest-volume prescribers was associated with only modestly higher risks of certain misuse measures among highest-use patients. The study suggests targeting policies to high prescribers and users may be more effective than broad policies.
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
This document summarizes a presentation on preventing opioid abuse and the role of dentists. It discusses current prescribing practices for acute dental pain that can lead to leftover opioids and abuse. It reviews evidence that combining different analgesics like NSAIDs and acetaminophen is more effective than single agents for acute pain. Guidelines are provided for managing acute pain with a multimodal analgesic approach and only using opioids if needed. The document contrasts acute versus chronic pain and notes opioids are not the primary strategy for most chronic orofacial pain conditions. It introduces the University of Kentucky Orofacial Pain Center's multidisciplinary approach to chronic pain management.
This document discusses a presentation on whether pharmacists should fill opioid prescriptions or not. It includes the presenters, learning objectives, and disclosures. It then summarizes Karen Ryle's presentation on red flags pharmacists should watch out for when dispensing controlled substances like opioids. These include things like "cocktailed" prescriptions, no individualized dosing, early refills, out-of-area doctors and patients, and mostly cash prescriptions. It also discusses integrating prescription drug monitoring program data into pharmacy workflows to more easily check for signs of abuse or diversion.
- WHO reviewed new evidence on the treatment of drug-resistant tuberculosis which informed updated guidelines.
- For eligible MDR-TB patients, a shorter all-oral regimen containing bedaquiline was found to have better outcomes than regimens containing injectables and may replace them.
- A novel 6-9 month regimen called BPaL showed high success for XDR-TB patients but requires more evaluation due to limited data and side effects before broad implementation.
- The 2020 WHO guidelines will provide more detailed recommendations incorporating this new evidence.
This document discusses dangerous opioid prescribing practices observed in workers' compensation claims and strategies to address them. It provides an overview of opioid use and outcomes in workers' compensation populations. Specific cases are presented that exemplify dangerous prescribing patterns, including high doses and long-term use. Approaches used by organizations to identify at-risk patients and claims are outlined, such as monitoring prescription data and conducting urine drug screens. Initiatives to resolve issues include education, implementing prescribing guidelines, interdisciplinary treatment teams, and coordinating care for patients needing detoxification or behavioral health support.
Comparative Effectiveness Research CER: A New Current In Pharmaceutical Bran...JGB1
The document discusses the rise of pharmaceutical comparative effectiveness research (CER) in the United States. CER provides insight into the clinical and cost effectiveness of different drug therapies. It is being driven by growing government and private payer interest in justifying healthcare costs. The federal government is a major funder of CER through agencies like AHRQ and NIH. For pharmaceutical companies, demonstrating strong CER performance can help gain preferred formulary placement and market position, while poor performance may disadvantage a drug. The document outlines considerations for a pharmaceutical brand to conduct its own pilot CER study to evaluate its drug against competitors.
This document summarizes a presentation on insights from state policies and interventions to curb prescription drug overdoses. It describes several interventions:
1) PRIMUM, a system in North Carolina that alerts prescribers to patients' risk of misusing or abusing opioids at the point of care.
2) A project in Rhode Island that developed protocols to improve opioid prescription safety for trauma patients, including alerts if prescriptions exceed dosage thresholds and requiring naloxone co-prescriptions.
3) A study in Pennsylvania that used Medicaid claims data to identify risk factors for opioid overdoses, such as high dosage and multiple prescribers/pharmacies, to target high-risk patients.
This document summarizes a presentation on drugs to watch including tramadol, hydrocodone, and naloxone. It includes:
- Disclosures from presenters declaring no conflicts of interest.
- Learning objectives focused on analyzing the impact of schedule changes for tramadol and hydrocodone, educating on tramadol dangers, and evaluating pharmacist perspectives on naloxone.
- Information presented on the drugs including their classifications, potencies, risks of abuse and addiction, and impacts of rescheduling hydrocodone and tramadol in California. Data showed decreased hydrocodone prescriptions but increased tramadol and overall opioid prescriptions, as well as increased over
This document discusses the Orphan Drug Act and rare disease policies. It provides background on the US Orphan Drug Act of 1983, which aims to facilitate rare disease drug development by providing incentives. Key points include that the Act defines rare diseases as affecting fewer than 200,000 people, and has led to over 450 approved orphan drugs. However, the document notes that rare disease policies and the Orphan Drug Act are not the same. It advocates for India to enact its own rare disease policies and definitions to improve diagnosis, treatment and research. The Organization for Rare Diseases India is working towards this goal.
Polypharmacy resource_JAN 15_NINA BARNETTZeshan Ahmed
This document provides resources to support the management of polypharmacy and deprescribing. It begins with an overview of key terms such as polypharmacy, oligopharmacy, and deprescribing. It then discusses the increase in polypharmacy among older adults and some of the risks associated with inappropriate polypharmacy. The document is structured to provide background information on polypharmacy, tools and initiatives to support practice, and references. It aims to assist healthcare professionals with medication reviews and decisions around deprescribing for patients taking multiple medications.
This document provides guidance on reviewing polypharmacy, which is the use of multiple medications. It is important to review polypharmacy because many elderly patients are on multiple drugs but around half may not be taken as prescribed and adverse drug reactions are common, especially with more comorbidities rather than age. The guidance aims to help practitioners review medications and potentially deprescribe those where risks outweigh benefits by providing tools and considerations. Key points are identifying high-risk patients for review, focusing on certain drug classes, and balancing multiple treatment guidelines for individual patient circumstances through comprehensive medication reviews.
The document provides an overview of the Canadian pharmaceutical market, highlighting several key trends that will affect pharmaceutical manufacturers. The Canadian market, while smaller than some other countries, still ranks among the top 10 globally in drug spending. Launching a drug in Canada can be profitable if manufacturers understand the specific nuances of the market, such as Canada's complex reimbursement system with both public and private insurance. Health technology assessments play an important role in reimbursement decisions. Manufacturers must tailor their reimbursement and launch strategies to the target payer market, whether public or private plans. Health economic evidence is also becoming increasingly important for market access, pricing, and contracting in Canada.
Team Lift: Predicting Medication AdherenceNeil Ryan
Medication adherence is a growing public health concern in the US. It is the extent to which patients are taking medications as prescribed by their healthcare providers. Simply put, are patients eating their pills on time?
We looked at patient data from Medicare part D program released by Centers for Medicare & Medicaid services. We built a prediction model to ascertain whether a patient would be adherent based on a variety of social, economic and behavioral aspects.
The document discusses issues around the marketing of pharmaceutical drugs. It notes that pharmaceutical marketing can influence doctors' prescribing decisions and priorities. Several studies cited found that doctors view drug sales representatives as an important source of information. The document then outlines a proposed research agenda to further examine the extent and impact of pharmaceutical marketing, including potential costs and benefits to health systems and policies around transparency. It concludes by noting concerns that extensive marketing practices could undermine affordable medical care.
Medication non-adherence is a growing concern, as it is increasingly associated with negative health outcomes and higher cost of care. Tackling the burden of non-adherence requires a collaborative, patient-centric approach that considers individual patient needs and results in intelligent interventions that combine high-tech with high-touch.
This document summarizes a presentation on best practices for treating opioid addiction in the criminal justice population. It outlines the challenges of treatment in this population and identifies best practices for using medication-assisted treatment (MAT) and behavioral therapy. The presentation reviews key points from the ASAM National Practice Guideline, including that MAT is the standard of care for opioid use disorder and should be continued, initiated, or made available for inmates. Discontinuing treatment can be dangerous and contradicts evidence-based practices. The implications discussed are that the guideline supports higher quality care for inmates and a rehabilitative approach, while also helping to address the opioid epidemic.
Stress Relief for Counselors: Work Life AuditWiley
This document discusses the importance of self-care for counselors and mental health professionals. It notes that while these professions are rewarding, they can also be emotionally and physically draining due to built-in stressors. It recommends that counselors perform a "work life self-care audit" by asking themselves 5 questions about where they spend their time at work, whether they take breaks to eat without interruptions, socialize with coworkers they enjoy, leave work to break up their routine, and hold meetings in more relaxing locations. Taking the answers into account can help counselors make small adjustments to their work routines to better care for themselves.
A 12-year-old female client wrote a suicide note and gave it to a friend after being molested by her stepfather for 2 years and 9 months. She previously attempted suicide. The client lives with her mother and has no siblings. She has a court appearance regarding the abuse and is increasingly frightened and depressed. The physician recommends inpatient treatment to address her suicide attempts and history of sexual abuse.
This study examined opioid prescribing patterns among Medicaid patients and providers in Oregon in 2013. It found that prescribing and use were highly concentrated, with the top 10% of providers accounting for over 80% of opioid prescriptions by morphine equivalent dose, and the top 10% of patients accounting for over 83% of doses. Patients in the highest decile of opioid use had higher rates of potential misuse indicators like prescription overlaps. While increasing opioid use overall was linked to higher misuse, receiving opioids from the highest-volume prescribers was associated with only modestly higher risks of certain misuse measures among highest-use patients. The study suggests targeting policies to high prescribers and users may be more effective than broad policies.
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
This document summarizes a presentation on preventing opioid abuse and the role of dentists. It discusses current prescribing practices for acute dental pain that can lead to leftover opioids and abuse. It reviews evidence that combining different analgesics like NSAIDs and acetaminophen is more effective than single agents for acute pain. Guidelines are provided for managing acute pain with a multimodal analgesic approach and only using opioids if needed. The document contrasts acute versus chronic pain and notes opioids are not the primary strategy for most chronic orofacial pain conditions. It introduces the University of Kentucky Orofacial Pain Center's multidisciplinary approach to chronic pain management.
This document discusses a presentation on whether pharmacists should fill opioid prescriptions or not. It includes the presenters, learning objectives, and disclosures. It then summarizes Karen Ryle's presentation on red flags pharmacists should watch out for when dispensing controlled substances like opioids. These include things like "cocktailed" prescriptions, no individualized dosing, early refills, out-of-area doctors and patients, and mostly cash prescriptions. It also discusses integrating prescription drug monitoring program data into pharmacy workflows to more easily check for signs of abuse or diversion.
- WHO reviewed new evidence on the treatment of drug-resistant tuberculosis which informed updated guidelines.
- For eligible MDR-TB patients, a shorter all-oral regimen containing bedaquiline was found to have better outcomes than regimens containing injectables and may replace them.
- A novel 6-9 month regimen called BPaL showed high success for XDR-TB patients but requires more evaluation due to limited data and side effects before broad implementation.
- The 2020 WHO guidelines will provide more detailed recommendations incorporating this new evidence.
This document discusses dangerous opioid prescribing practices observed in workers' compensation claims and strategies to address them. It provides an overview of opioid use and outcomes in workers' compensation populations. Specific cases are presented that exemplify dangerous prescribing patterns, including high doses and long-term use. Approaches used by organizations to identify at-risk patients and claims are outlined, such as monitoring prescription data and conducting urine drug screens. Initiatives to resolve issues include education, implementing prescribing guidelines, interdisciplinary treatment teams, and coordinating care for patients needing detoxification or behavioral health support.
Comparative Effectiveness Research CER: A New Current In Pharmaceutical Bran...JGB1
The document discusses the rise of pharmaceutical comparative effectiveness research (CER) in the United States. CER provides insight into the clinical and cost effectiveness of different drug therapies. It is being driven by growing government and private payer interest in justifying healthcare costs. The federal government is a major funder of CER through agencies like AHRQ and NIH. For pharmaceutical companies, demonstrating strong CER performance can help gain preferred formulary placement and market position, while poor performance may disadvantage a drug. The document outlines considerations for a pharmaceutical brand to conduct its own pilot CER study to evaluate its drug against competitors.
This document summarizes a presentation on insights from state policies and interventions to curb prescription drug overdoses. It describes several interventions:
1) PRIMUM, a system in North Carolina that alerts prescribers to patients' risk of misusing or abusing opioids at the point of care.
2) A project in Rhode Island that developed protocols to improve opioid prescription safety for trauma patients, including alerts if prescriptions exceed dosage thresholds and requiring naloxone co-prescriptions.
3) A study in Pennsylvania that used Medicaid claims data to identify risk factors for opioid overdoses, such as high dosage and multiple prescribers/pharmacies, to target high-risk patients.
This document summarizes a presentation on drugs to watch including tramadol, hydrocodone, and naloxone. It includes:
- Disclosures from presenters declaring no conflicts of interest.
- Learning objectives focused on analyzing the impact of schedule changes for tramadol and hydrocodone, educating on tramadol dangers, and evaluating pharmacist perspectives on naloxone.
- Information presented on the drugs including their classifications, potencies, risks of abuse and addiction, and impacts of rescheduling hydrocodone and tramadol in California. Data showed decreased hydrocodone prescriptions but increased tramadol and overall opioid prescriptions, as well as increased over
This document discusses the Orphan Drug Act and rare disease policies. It provides background on the US Orphan Drug Act of 1983, which aims to facilitate rare disease drug development by providing incentives. Key points include that the Act defines rare diseases as affecting fewer than 200,000 people, and has led to over 450 approved orphan drugs. However, the document notes that rare disease policies and the Orphan Drug Act are not the same. It advocates for India to enact its own rare disease policies and definitions to improve diagnosis, treatment and research. The Organization for Rare Diseases India is working towards this goal.
Polypharmacy resource_JAN 15_NINA BARNETTZeshan Ahmed
This document provides resources to support the management of polypharmacy and deprescribing. It begins with an overview of key terms such as polypharmacy, oligopharmacy, and deprescribing. It then discusses the increase in polypharmacy among older adults and some of the risks associated with inappropriate polypharmacy. The document is structured to provide background information on polypharmacy, tools and initiatives to support practice, and references. It aims to assist healthcare professionals with medication reviews and decisions around deprescribing for patients taking multiple medications.
This document provides guidance on reviewing polypharmacy, which is the use of multiple medications. It is important to review polypharmacy because many elderly patients are on multiple drugs but around half may not be taken as prescribed and adverse drug reactions are common, especially with more comorbidities rather than age. The guidance aims to help practitioners review medications and potentially deprescribe those where risks outweigh benefits by providing tools and considerations. Key points are identifying high-risk patients for review, focusing on certain drug classes, and balancing multiple treatment guidelines for individual patient circumstances through comprehensive medication reviews.
The document provides an overview of the Canadian pharmaceutical market, highlighting several key trends that will affect pharmaceutical manufacturers. The Canadian market, while smaller than some other countries, still ranks among the top 10 globally in drug spending. Launching a drug in Canada can be profitable if manufacturers understand the specific nuances of the market, such as Canada's complex reimbursement system with both public and private insurance. Health technology assessments play an important role in reimbursement decisions. Manufacturers must tailor their reimbursement and launch strategies to the target payer market, whether public or private plans. Health economic evidence is also becoming increasingly important for market access, pricing, and contracting in Canada.
Team Lift: Predicting Medication AdherenceNeil Ryan
Medication adherence is a growing public health concern in the US. It is the extent to which patients are taking medications as prescribed by their healthcare providers. Simply put, are patients eating their pills on time?
We looked at patient data from Medicare part D program released by Centers for Medicare & Medicaid services. We built a prediction model to ascertain whether a patient would be adherent based on a variety of social, economic and behavioral aspects.
The document discusses issues around the marketing of pharmaceutical drugs. It notes that pharmaceutical marketing can influence doctors' prescribing decisions and priorities. Several studies cited found that doctors view drug sales representatives as an important source of information. The document then outlines a proposed research agenda to further examine the extent and impact of pharmaceutical marketing, including potential costs and benefits to health systems and policies around transparency. It concludes by noting concerns that extensive marketing practices could undermine affordable medical care.
Medication non-adherence is a growing concern, as it is increasingly associated with negative health outcomes and higher cost of care. Tackling the burden of non-adherence requires a collaborative, patient-centric approach that considers individual patient needs and results in intelligent interventions that combine high-tech with high-touch.
This document summarizes a presentation on best practices for treating opioid addiction in the criminal justice population. It outlines the challenges of treatment in this population and identifies best practices for using medication-assisted treatment (MAT) and behavioral therapy. The presentation reviews key points from the ASAM National Practice Guideline, including that MAT is the standard of care for opioid use disorder and should be continued, initiated, or made available for inmates. Discontinuing treatment can be dangerous and contradicts evidence-based practices. The implications discussed are that the guideline supports higher quality care for inmates and a rehabilitative approach, while also helping to address the opioid epidemic.
Stress Relief for Counselors: Work Life AuditWiley
This document discusses the importance of self-care for counselors and mental health professionals. It notes that while these professions are rewarding, they can also be emotionally and physically draining due to built-in stressors. It recommends that counselors perform a "work life self-care audit" by asking themselves 5 questions about where they spend their time at work, whether they take breaks to eat without interruptions, socialize with coworkers they enjoy, leave work to break up their routine, and hold meetings in more relaxing locations. Taking the answers into account can help counselors make small adjustments to their work routines to better care for themselves.
A 12-year-old female client wrote a suicide note and gave it to a friend after being molested by her stepfather for 2 years and 9 months. She previously attempted suicide. The client lives with her mother and has no siblings. She has a court appearance regarding the abuse and is increasingly frightened and depressed. The physician recommends inpatient treatment to address her suicide attempts and history of sexual abuse.
The opioid renewal clinic a primary care managed approachPaul Coelho, MD
This document describes a study evaluating the impact of an Opioid Renewal Clinic (ORC) program at a Veterans Affairs Medical Center. The ORC was established to support primary care providers in safely managing patients with chronic pain requiring opioid therapy. It was led by a nurse practitioner and clinical pharmacist, supported by a multidisciplinary pain team. The ORC utilized opioid treatment agreements and urine drug testing. The program resulted in improved adherence for many patients, identification and treatment of substance abuse issues for some, and cost savings for the hospital pharmacy. It provided primary care providers a structured approach for managing complex chronic pain patients on long-term opioid therapy.
The document discusses the Stop Selling Heroin organization, which aims to combat heroin abuse and overdoses in Cape May County, New Jersey. It provides background on the heroin epidemic in the county, with over 50 deaths in 2012. The organization wants to approach drug dealers and users through their friends and family to encourage support groups and resources. It also includes a sample buyer persona, examples of social media use and advertising, and an initial media budget.
The document discusses efforts to address the opioid epidemic in the United States, including:
- Increasing registration and use of prescription drug monitoring programs (PDMPs) to track opioid prescriptions.
- Reducing the stigma around both pain and substance use disorder to increase access to comprehensive treatment.
- Expanding access to naloxone to prevent overdose deaths and "Good Samaritan" legal protections.
- Ongoing education of physicians on safe opioid prescribing and alternative pain management strategies.
National Academies of Science and Medicine: Intertwined Epidemics: Opioid and...Dan Ciccarone
This document summarizes research on the intertwined opioid and heroin epidemics in the United States. It discusses trends showing rising overdose rates for both opioids and heroin since the 1990s. Qualitative interviews suggest many individuals transition from misusing prescription opioids to heroin. The epidemics are intertwined as the at-risk populations overlap and many initiate heroin use after developing dependency from prescription opioids. However, the heroin epidemic also involves a "heroin pull" from increased heroin availability and new forms of heroin being supplied. Ongoing challenges include addressing excessive opioid prescribing, improving surveillance of heroin products and use patterns, expanding treatment programs, and implementing harm reduction strategies.
New Castle County police announced a new approach to fighting
the heroin epidemic with components of a similar strategy initiated
by police in Gloucester, Massachusetts.
Daniel Blaney-Koen, American Medical Association, presented on The Nation's Opioid Epidemic: Are we Asking the Right Questions? at the State Legislative Conference on November 6, 2015.
The document summarizes the opioid epidemic in the United States and the response from the Department of Health and Human Services (HHS). It provides data showing that prescription opioids are the most commonly abused drugs and that opioid overdose deaths have increased significantly since 1999. The HHS Secretary launched an Opioid Initiative in 2015 focused on improving opioid prescribing practices, increasing access to naloxone to reverse overdoses, and expanding medication-assisted treatment for opioid use disorders. Partnerships with health organizations aim to train providers and increase access to prevention and treatment services. States like Washington that implemented comprehensive approaches have seen declines in overdose deaths and hospitalizations.
The document discusses the epidemiology and complications of illicit opioid use. It summarizes prevalence rates of heroin use in Australia, risk factors for developing problems, and associated medical and psychosocial risks like infections, overdose, mental health issues, and social consequences. Prescription opioid use and responsible prescribing are also briefly mentioned.
Heroin is an illegal and highly addictive drug derived from opium. It is typically taken by injection but can also be smoked or snorted. Use of heroin leads to a euphoric high but also serious health risks like overdose from the unpredictable potency of street drugs. The United States is experiencing a heroin epidemic, with a 50% rise in heroin use from 2002-2012 and over 680,000 people using heroin annually in 2013. Massachusetts alone saw over 200 heroin overdoses in a 3 month period of 2015. Treatment options for addiction include detox centers, counseling, therapy, and medication assistance programs.
1) Prescription drug abuse in the U.S. has reached epidemic levels, with overdose deaths, opioid sales, and treatment admissions all rising in parallel since 1999. 2) To reverse the epidemic, efforts are needed to improve prescription drug monitoring programs (PDMPs), ensure safer opioid prescribing practices, expand access to treatment including buprenorphine, and support state-level prevention strategies. 3) Early evidence suggests that real-time, universal PDMPs; mandating their use; integrating them into electronic health records; and comprehensive laws can all help to reduce doctor shopping, opioid prescribing, and overdose deaths.
Looking for a solution to the workers' compensation opioid abuse? Check out Modern Medical's proactive program. Opioid Defense Manager™, protecting your employees, the physicians and you.
The document discusses the opioid epidemic in the United States, focusing on the role of OxyContin. It describes how OxyContin became widely prescribed due to a shift in pain treatment philosophy in the 1980s, an aggressive marketing campaign by Purdue Pharma claiming the drug had a low addiction risk, and changes in physician prescribing habits. However, OxyContin proved to be highly addictive, and increased opioid prescriptions correlated with rising overdose rates. Purdue Pharma was later found to have misleadingly marketed OxyContin and paid fines, but the epidemic had already taken hold across the nation. The FDA and state governments have since implemented measures to curb inappropriate opioid prescribing and monitor distribution.
This document summarizes a presentation given by Dr. Michael M. Miller on the prescription drug epidemic in the United States. It discusses how increased recognition of pain and addiction as medical conditions has led to more opioid prescriptions being written, resulting in higher rates of addiction, overdoses and deaths. While aiming to improve care, policies promoting greater opioid prescribing have had unintended consequences. The shortage of specialists means general physicians often lack training to safely evaluate and treat pain or addiction. Rising opioid prescription drug abuse now poses a major public health crisis in the U.S.
This document discusses the importance of treatment for opioid use disorders. It notes the rise in prescription pain medication abuse and related harms like overdoses. Treatment options like medication-assisted treatment with drugs like methadone and buprenorphine combined with counseling can effectively treat opioid addiction, improving health and social outcomes. The Substance Abuse and Mental Health Services Administration promotes such evidence-based treatment approaches and prevention efforts to address the prescription drug abuse epidemic.
The director of the CDC discussed the prescription drug and opioid overdose epidemic in the United States. He noted that over 145,000 lives have been lost to prescription opioid overdoses in the past decade as opioid prescribing has increased 4-fold since 1999. The CDC is working with multiple states experiencing outbreaks of HIV linked to injection drug use. The director outlined a potential "technical package" of interventions including improving prescribing practices, increasing access to treatment, reducing drug availability, and public awareness campaigns. Progress requires a comprehensive, evidence-based public health approach with law enforcement and community involvement.
This document summarizes a presentation on technologies to reduce prescription drug diversion, fraud, and abuse through electronic prescribing and drug deactivation systems. It discusses Delaware's pilot program with an at-home drug deactivation system. The presentation describes how electronic prescribing of controlled substances can reduce diversion and fraud while improving patient satisfaction. It also outlines DEA requirements for electronic prescribing and discusses Cambridge Health Alliance's experience implementing electronic prescribing of controlled substances with Epic and Imprivata. Finally, it summarizes the results of Delaware's pilot program, which provided at-home drug deactivation systems to specific pharmacies to promote safe disposal of unused prescription drugs.
Intro to Prevention: Psychopharmacology Guest LectureJulie Hynes
Current A&D Conditions in lane County: And why we need prevention. Guest lecturer: Julie Hynes, MA, RD, CPS - PreventionLane at Lane County Public Health
This document summarizes safety precautions for high-alert medications. It identifies several categories of medications considered high-risk, including anticoagulants, digoxin, electrolytes, insulin, narcotics, and sedatives. Surveys found practitioners identify more medications as high-alert than organizations officially designate. Recommendations are provided for organizational safety policies and individual nursing practices like independent double checks and monitoring. The top root causes of medication-related adverse events are identified as human factors, the physical environment, and communication issues.
Influence of medicare formulary restrictions on evidence based prescribing pr...TÀI LIỆU NGÀNH MAY
Để xem full tài liệu Xin vui long liên hệ page để được hỗ trợ
: https://www.facebook.com/thuvienluanvan01
HOẶC
https://www.facebook.com/garmentspace/
https://www.facebook.com/thuvienluanvan01
https://www.facebook.com/thuvienluanvan01
tai lieu tong hop, thu vien luan van, luan van tong hop, do an chuyen nganh
Defined daily dose-DDD
B Pharm, Pharm D and medicine syllabus
Useful for examination and regulatory function information
Useful for Pharmacovigilance interview and medical coding also.
Good Luck and all the best!!!
This document provides an overview of principles of pharmacology for Advanced EMTs. It includes objectives that cover key terms, medication sources, legislation regarding prescription medications, medication names, forms, packaging, profiles, and pharmacokinetics. Special considerations for medications in pregnant patients, pediatrics, and geriatrics are also addressed. The document contains tables on medication schedules, FDA pregnancy categories, adrenergic receptors, and classifications of medications.
This document provides an overview of medication administration and pharmacology terms. It defines key terms like drug, pharmacology, pharmacokinetics, and clinical pharmacology. It also outlines the ideal properties of drugs and factors that determine drug responses. The nursing process in relation to pharmacology is discussed, including assessing patients, planning treatment, evaluating responses, and educating patients. Regulations around drug names, sources of information, and the FDA are also summarized.
The document discusses medication errors and the need for a comprehensive approach to reduce preventable errors. It reports that at least 1.5 million preventable adverse drug events occur each year in the US, costing $3.5 billion annually. The National Centers for Education and Research on Therapeutics (CERTS) were established to conduct research and provide education to optimize drug use, reduce errors and adverse events, and improve patient outcomes and health. CERTS focuses on research and web-based education for professionals and consumers around safe medication use.
Concept of essential medicines and rational use of medicinesVivek Nayak
This document discusses essential medicines and rational drug use. It defines essential medicines as those that meet the priority health care needs of the population based on efficacy, safety and cost-effectiveness. The WHO publishes a model list of essential medicines that is divided into core and complementary items. Rational drug use means using the appropriate medicine at the right dose for the correct duration. Promoting rational use involves training, continuing education, and formulary guidance. Irrational use increases costs and harms patients.
An Essential Drug List, also known as a core drug list or medication list, is a carefully selected inventory of medications that are deemed essential for addressing the most prevalent health conditions within a specific population or country. It serves as a key component of national drug policies and pharmaceutical programs, ensuring the availability, accessibility, and affordability of essential medicines. The list is typically developed based on rigorous criteria, taking into consideration the medications' safety, efficacy, cost-effectiveness, and suitability for primary healthcare settings.
Rational Drug Therapy refers to the systematic and evidence-based approach to prescribing medications, aiming to maximize therapeutic benefits while minimizing the risk of adverse effects. It involves following established therapeutic guidelines and clinical protocols to ensure that medications are prescribed in a manner that is appropriate for the patient's condition, taking into account factors such as age, weight, co-existing conditions, drug interactions, and individual response. Rational drug therapy promotes the use of medications based on sound scientific evidence, emphasizing the principles of efficacy, safety, and cost-effectiveness to optimize patient outcomes and improve overall healthcare quality.
This document summarizes a presentation on engaging physicians in prevention efforts to address the opioid epidemic. It was presented by Yngvild Olsen and included the following key points:
1. Multiple policies like PDMPs, medication-assisted treatment, and naloxone access need to work together to reduce opioid misuse and overdoses.
2. Programs that educate physicians about prescription drug abuse and its link to heroin, and engage them in prevention, screening, and treatment can help address the epidemic.
3. Expanding access to evidence-based treatment with medications like buprenorphine and naloxone, combined with behavioral therapies, can help manage opioid addiction as a chronic disease
Drug and alcohol use by dental healthcare professionals and studentsGeorge Kenna
- Dentists have higher rates of alcohol use compared to other healthcare professionals but similar rates of illicit drug use. Their drug use does not exceed rates in the general population.
- There is no strong evidence that suicide rates are higher among dentists compared to other occupations.
- Identifying substance use disorders in colleagues involves looking for behavioral and work performance signs such as changes in appearance, absenteeism, and deterioration in skills.
- Treatment for substance use typically involves inpatient treatment followed by outpatient counseling and 12-step programs, with most dentists successfully returning to practice with monitoring.
This Pill Will Help You Feel Better: Final ProjectHans Mundahl
This document summarizes a Junior Urban Adventure presentation about pharmaceuticals, healthcare, and addiction. It discusses perspectives from a drug rehabilitation center called Hello House, the Massachusetts College of Pharmacy and Health Sciences, and the pharmaceutical company Merck. At Hello House, students learned about its 12-step program and saw its high success rates for helping men recover from drug and alcohol addictions. They also visited MCPHS to explore educational opportunities in healthcare fields. At Merck, they gained insight into the drug development process and clinical trials. Overall, the presentation provided students with a better understanding of difficult issues around addiction, healthcare, and the pharmaceutical industry.
Global Medical Cures™ | Responding to America's Prescription Drug Abuse CrisisGlobal Medical Cures™
This document summarizes the growing problem of prescription drug abuse in America. Key points include:
- Prescription drug abuse is now the nation's fastest growing drug problem, with opioids like oxycodone being abused at increasing rates.
- Education of healthcare providers, patients, and the public is needed to increase awareness of the dangers of prescription drug misuse and how to properly use and dispose of medications.
- Tracking programs like prescription drug monitoring programs (PDMPs) in states can help identify "doctor shoppers" and reduce diversion, though more research is still needed on their effectiveness.
- A multifaceted approach including education, monitoring, safe disposal, and enforcement is needed to address the crisis of prescription drug
This study examined the association between initial opioid prescribing patterns and the likelihood of long-term opioid use among patients who were opioid-naïve. The study used prescription drug monitoring program data from Oregon to identify over 500,000 patients who filled their first opioid prescription between 2012-2013. It found that receiving multiple prescriptions or higher total morphine milligram equivalents in the first 30 days was associated with greater odds of long-term opioid use (defined as 6 or more fills) in the following year. Patients who started on long-acting opioids also had higher risk than those starting on short-acting drugs. The associations remained after excluding patients likely using opioids for cancer or end-of-life care.
The document discusses key terms used when discussing pain medications and risk management. It defines terms like abuse, addiction, physical dependence, pseudoaddiction, and tolerance to encourage accurate use of terminology and promote better patient care and regulatory policies. Uncontrolled pain is an enormous public health problem, already costing tens of billions annually. Relieving pain is fundamental to public health, as recognized by many medical and regulatory organizations.
This document discusses pharmacoeconomics in the Indian context. It begins by introducing the field of pharmacoeconomics and its growing importance in India given the large population and relatively scarce healthcare resources. It then provides an overview of how pharmacoeconomics can inform decisions regarding drug licensing, reimbursement, and formulary procedures. The role of pharmacology graduates in applying pharmacoeconomic principles to improve resource allocation in community and tertiary hospitals is also discussed.
This document provides an overview of drug utilization research (DUR). It defines DUR as the marketing, distribution, prescription, and use of drugs in a society and its resulting medical, social and economic consequences. The document outlines the history, levels, aspects, study designs, and guidelines for DUR based on WHO standards. It describes quantitative and qualitative DUR approaches and explains indicators like the Anatomical Therapeutic Chemical classification system and Defined Daily Dose concept for standardized DUR analysis. The goal of DUR is to promote rational and appropriate drug use.
1. Co-prescribing opioids and benzodiazepines poses serious health risks like respiratory depression and increased risk of overdose death. Delaware has high rates of prescriptions for these drugs.
2. Delaware's PDMP collects prescription data that can help identify patients and providers with troubling patterns of co-prescribing to reduce risks. Regular screening and urine tests can also help address misuse.
3. PDMP data analysis found that in 2013 over 12% of individuals in Delaware filled prescriptions for both drug classes, putting them at risk. The PDMP is a valuable tool to improve prescribing practices and detect misuse.
Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. WHO established its Programme for International Drug Monitoring in response to the thalidomide disaster detected in 1961. Together with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, WHO promotes PV at the country level. At the end of 2010, 134 countries were part of the WHO PV Programme. The aims of PV are to enhance patient care and patient safety in relation to the use of medicines; and to support public health programmes by providing reliable, balanced information for the effective assessment of the risk-benefit profile of medicines.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Kana Enomoto, Acting Administrator, Substance Abuse and Mental Health Services Administration, keynote presentation at the National Rx Drug Abuse & Heroin Summit March 29, 2016
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
This document discusses the role of health departments in preventing neonatal abstinence syndrome (NAS). It notes that NAS rates have increased significantly in recent years, disproportionately affecting women. Health departments engage in surveillance to monitor NAS trends, partner with other organizations, support treatment and recovery programs, and provide education to prevent NAS, which is entirely preventable. The document outlines specific strategies health departments use across these areas to address the opioid epidemic and protect maternal and infant health.
The document discusses the opioid crisis in the United States, including rising rates of prescription opioid misuse and abuse, as well as heroin use and overdose deaths. It outlines how research can help address this crisis through developing less abusable analgesics, expanding access to treatment medications like naloxone and buprenorphine, and exploring new treatment approaches such as immunotherapies and precision medicine targeting genetic factors. The National Institute on Drug Abuse is supporting these research efforts and working to disseminate findings to improve prevention and intervention programs.
This document summarizes the opioid crisis in the United States from 2000 to 2014. It shows that the number of opioid-related overdose deaths more than tripled during this period, increasing from about 8,000 to over 28,000. Additionally, 7.9 million Americans aged 12 or older met the criteria for an illicit drug use disorder in 2013-2014 but only 20% received treatment. The document outlines actions by the Obama administration to address the crisis and increase funding for treatment. It emphasizes that stories can help reduce stigma and that recovery is possible through working together.
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
This presentation covered multi-media prevention strategies for issues like prescription drug overdoses. It discussed the CDC's digital Rx drug prevention campaign, best practices for digital messaging, and programs using expectancy challenge theory and media literacy education in schools. Presenters included representatives from the CDC, Media Literacy for Prevention, and the Hanley Center Foundation who discussed their work developing and implementing digital communications and single-session prevention programs.
This document discusses strategies for reducing buprenorphine diversion and pill mills while improving access to treatment. It notes that limiting access to buprenorphine treatment is associated with increased diversion, while expanded access to quality treatment decreases diversion and overdose deaths. The document recommends educating prescribers, using medically-derived prescribing standards, ensuring adequate insurance coverage of safe prescribing practices, and addressing diversion risks for other controlled medications. It argues against onerous new regulations that could limit treatment access. The goal is to identify and support high-quality treatment while prosecuting criminal operations.
This document summarizes a presentation on linking and mapping prescription drug monitoring program (PDMP) data. It discusses the benefits of linking PDMP data to clinical data, including improving patient safety, evaluating prescribing decisions, and assessing the impact of PDMP interventions. It describes challenges with linking data, such as obtaining consent and negotiating data use agreements. It also discusses Washington State's MAPPING OPIOID AND OTHER DRUG ISSUES (MOODI) tool, which integrates PDMP data with other databases to map and target treatment and overdose prevention efforts at the community level.
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
This document discusses workplace issues related to prescription drug abuse and strategies for prevention. It begins with introductions of the presenters and moderators. The learning objectives are then outlined as understanding challenges of prescription drug abuse in the workplace, identifying prevention strategies, and describing programs available through SAMHSA. The document then covers topics such as the scope of prescription drug misuse among workers, risks to the workplace, prevention strategies employers can consider, and available resources from SAMHSA.
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
This document discusses a presentation on pharmacy burglary, robbery, and diversion of prescription drugs. The presentation covers trends in prescription drug diversion, particularly those involving robbery and burglary of pharmacies. It identifies preventative measures to enhance pharmacy security and safety. Strategies to reduce pharmacy crimes are outlined. The offender perspective is examined based on interviews with convicted offenders. Routine activities theory is discussed as relating to suitable targets, capable guardians, and motivated offenders. Partnerships between regulatory agencies and law enforcement are emphasized as key to prevention efforts.
Linking and mapping PDMP data can provide several benefits but also faces challenges. Linking PDMP and clinical data allows for evaluating the impact of PDMP interventions on outcomes and prescribing decisions. However, obtaining permissions and data is difficult due to legal and resource barriers. Mapping PDMP data using GIS tools in Washington identified areas for targeting overdose prevention efforts by visualizing patterns in prescribing risks, treatment availability, and overdoses. Stakeholders used these maps to guide education and funding decisions. Sustaining these tools requires ongoing funding and expanding included data sources.
This document discusses drug court models and the role of law enforcement in drug courts. It begins with introductions from presenters and outlines learning objectives about explaining drug court operations and benefits, how law enforcement can utilize drug courts, and identifying best practices. The following sections provide details on drug court models, including how they integrate treatment into the justice system using a non-adversarial approach. Key components of drug courts are outlined, and presenters discuss issues like prescription drug and heroin abuse as well as outcomes from drug courts in reducing recidivism and saving money. Law enforcement can play roles in prevention, addressing domestic violence, and targeting the right populations for drug court involvement through assessment.
This document summarizes presentations from two communities - Huntington, WV and Camden County, NJ - on their responses to heroin crises. It outlines programs implemented in Huntington, including a harm reduction program, centralized information system, and drug court expansion. It also discusses the region's history with prescription drug abuse and rise in heroin and associated issues like hepatitis and neonatal abstinence syndrome. Long-term strategies proposed include expanding treatment services, promoting career opportunities for those in recovery, and preventing relapse through environmental design changes.
This document discusses neonatal abstinence syndrome (NAS) and universal maternal drug testing. It provides background information on NAS including trends showing large increases in incidence and costs associated with NAS. It outlines objectives related to describing NAS trends, identifying legislative activities impacting NAS, describing family planning for women in substance abuse treatment, and explaining a hospital program using universal drug testing. The document then covers topics including NAS symptoms, incidence and geographic trends, costs of NAS, opioid use in women of childbearing age, unintended pregnancy rates, contraceptive use among opioid users, and maternal drug exposure sources.
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
This document outlines an advocacy track presentation on activating communities to address prescription drug abuse. It provides biographies of the presenters and moderators and discloses any conflicts of interest. The learning objectives are to identify best practices for implementing CADCA's seven strategies for community change to impact prescription drug issues. It then provides examples of how various coalitions across the country are utilizing each of the seven strategies, such as providing education, enhancing skills, supporting communities, and changing policies.
This document discusses recovery ready ecosystems and recovery community organizations. It introduces presenters from Young People in Recovery and Hope House Treatment Track who will discuss interventions, prevention, and recovery programs. Examples of Young People in Recovery chapters, programs, and services are provided, including employment workshops, education workshops, housing workshops, and recovery support services. The document also discusses recovery community organizations and initiatives in Texas and Georgia, such as the Association of Persons Affected by Addiction in Dallas and the Georgia Council on Substance Abuse.
This document summarizes a presentation on health plan involvement in safe prescribing. It includes:
1) Presentations from medical experts on prescription drug abuse trends from medical examiner data and a tribal health system's safe prescribing program.
2) A discussion of health plan policies to reduce "red flag" medication combinations like opioids plus benzodiazepines through prior authorization, formulary changes, and provider restrictions.
3) Examples of one health plan's implementation of policies like restricting methadone prescriptions to pain specialists and removing carisoprodol from its formulary.
This document summarizes a presentation on youth performance-enhancing drugs and ADHD medication. It discusses trends in misuse of these substances among young people. The presentation is given by representatives from various organizations focused on prevention, health promotion, and substance abuse issues among youth and college students. The presentation covers types of performance-enhancing drugs and their potential side effects. It also discusses trends in attitudes towards these substances and risks of misuse. Strategies are presented for helping adolescents pursue their goals without these drugs. The document concludes by outlining plans for addressing misuse of ADHD medication among college students through education and collaboration between various stakeholder groups.
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
This presentation gives information on the pharmacology of Prostaglandins, Thromboxanes and Leukotrienes i.e. Eicosanoids. Eicosanoids are signaling molecules derived from polyunsaturated fatty acids like arachidonic acid. They are involved in complex control over inflammation, immunity, and the central nervous system. Eicosanoids are synthesized through the enzymatic oxidation of fatty acids by cyclooxygenase and lipoxygenase enzymes. They have short half-lives and act locally through autocrine and paracrine signaling.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.